Mednet Logo
HomeRheumatology
Rheumatology

Rheumatology

Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.

Recent Discussions

How would you apprach a SLE patient who is planning pregnancy on hydroxychloroquine with a high titer dsDNA who cannot tolerate azathioprine and whose only symptom is arthralgia?

1 Answers

Mednet Member
Mednet Member
Rheumatology · UT Southwestern Medical Center

In an SLE patient planning pregnancy whose only clinical manifestation is arthralgia, hydroxychloroquine monotherapy is appropriate. During the pregnant and non-pregnant state, additional immunosuppression is not indicated for a high titer dsDNA; rather, monitoring for organ manifestations is approp...

What is your approach to escalating therapies for stiff person syndrome that is refractory to IVIG and steroids?

1 Answers

Mednet Member
Mednet Member
Neurology · University of Minnesota

Step 1: Make sure the diagnosis is correct, especially if seronegative or very weakly positive for GAD65 antibodies.Misdiagnosis of SPS is common and diagnostic criteria have been recently proposed (Reference 1). Patients who complain of subjective stiffness/muscle spasms, but do not have objective ...

Are the results of the SEAM-RA trial generalizable to other TNF inhibitors given the differences in immunogenicity?

1 Answers

Mednet Member
Mednet Member
Rheumatology · University of Alabama

This is a great question, and an important one because different TNF inhibitors have different immunogenicity and patients can make anti-drug antibodies that can effectively neutralize the drug and render it a less effective treatment option. This tends to happen more with some molecular constructs ...

Do you routinely check morning cortisol before discharging a patient who received more than 3 days of high-dose corticosteroids during a hospitalization for an acute illness?

3 Answers

Mednet Member
Mednet Member
Endocrinology · Johns Hopkins Endocrinology and Pituitary Center

No. In general, persistent HPA suppression does not occur when a single steroid treatment is shorter than 2 weeks.

How would you approach evaluation and management of a patient with chronic arthralgias and bilateral hand weakness who has a positive ANA (1:160) and low-titer anti-SSB positivity, in the setting of otherwise negative ENA panel, normal inflammatory markers, normal complement levels and immunoglobulins, and unrevealing EMG/NCS testing?

5 Answers

Mednet Member
Mednet Member
Rheumatology · University of California, Berkeley and San Francisco

The low titer SSB/La antibody would only factor into the consideration of SjD if there were other suggestive features, like documented hypo salivation and/or high ocular staining score, neuropathy, etc. Would learn when they were totally well and what potential triggering events may have occurred. I...

Do you routinely recommend delaying dental extractions in patients who have recently received intravenous bisphosphonate therapy for osteoporosis treatment?

1 Answers

Mednet Member
Mednet Member
Endocrinology · Kaiser Permanente Oakland Medical Center Endocrinology

I don't because the risk of osteonecrosis of the jaw (ONJ) is very low.

How do you counsel patients with GCA on the benefits of steroids who have already experienced vision loss?

1
3 Answers

Mednet Member
Mednet Member
Neurology · The University of Iowa

I first tell the patient they are at considerable risk for further visual loss in the same eye or the other eye over the next 1-2 weeks. I also let them know that, even though their risk of visual loss has been reduced, their best option for preventing further visual loss is immediately starting hig...

Would you start romosozumab in an active smoker?

1
1 Answers

Mednet Member
Mednet Member
Rheumatology · U of AZ Phoenix Dept of Orthopaedics

This is not simple! But we are good at assessment of risk vs benefit (or benefit vs risk!)First I would reassess fracture risk, prior treatments, reason to consider romo. Then I would do a deep dive into risk assessment for cardiovascular disease: how much do they smoke, prior cardiovascular disease...

When stopping denosumab and transitioning to PO bisphosphonate, do you wait for 6 months after the last denosumab injection to start PO bisphosphonate?

3
2 Answers

Mednet Member
Mednet Member
Rheumatology · Icahn School of Medicine at Mount Sinai

Some background: In patients discontinuing denosumab without subsequent antiresorptive therapy, BMD rapidly reverts back to baseline with an elevation in vertebral fracture risk (with an enhanced risk of multiple vertebral fractures). Thus, sequential treatment regimens following denosumab have been...

How soon after a fracture would it be safe to start anti-resorptive therapy?

3 Answers

Mednet Member
Mednet Member
Rheumatology · U of AZ Phoenix Dept of Orthopaedics

This is an important question. There is no definitive answer, and there have been no clinical or preclinical studies that demonstrate delayed healing in the presence of bisphosphonates. Personally, I favor waiting a few weeks before we start. That also gives us time to do a proper metabolic workup. ...